Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss

International Journal of Obesity

Volumn 35, Issue 11, 2011, Pages 1377-1384

  Bennetzen, M F ^a   Wellner, N ^b   Ahmed, S S ^b   Ahmed, S M ^b   Diep, T A ^b   Hansen, H S ^b   Richelsen, B ^a   Pedersen, S B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

adipose tissue; CB1; endocannabinoids; weight loss

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; METHIONINE GAMMA LYASE;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEAN BODY WEIGHT; MALE; MASS SPECTROMETRY; OBESITY; PRIORITY JOURNAL; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

ADULT; BODY COMPOSITION; BODY MASS INDEX; ENDOCANNABINOIDS; FASTING; FEMALE; GENE EXPRESSION; HUMANS; MALE; OBESITY; RECEPTOR, CANNABINOID, CB1; REFERENCE VALUES; SUBCUTANEOUS FAT; WEIGHT LOSS;

EID: 81155134826     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.8     Document Type: Article

References (38)

1. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843. (Pubitemid 41401077)
2. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060. (Pubitemid 44923642)
3. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699. (Pubitemid 46482358)
4. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 2010; 5: e8792.
5. Maccarrone M, Gasperi V, CataniMV, Diep TA, Dainese E, Hansen HS et al. The endocannabinoid system and its relevance for nutrition. Ann Rev Nutr 2010; 30: 423-440.
6. Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 2009; 58: 361-367.
7. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-1367.
8. Bordicchia M, Battistoni I, Mancinelli L, Giannini E, Refi G, Minardi D et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism 2010; 59: 734-741.
9. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR et al. International Union of Pharmacology. Cannabinoid Receptors and their Ligands: Beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
10. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-2704. (Pubitemid 351520576)
11. Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006; 29(3 Suppl): 15-26.
12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
13. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006; 126: 177-187.
14. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008; 108: 1687-1707. (Pubitemid 351796405)
15. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45: 405-446.
16. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009; 78: 553-560.
17. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009; 23: 1-15.
18. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006; 5: 272-292.
19. Rosenson RS. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology 2009; 114: 212-225.
20. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 1976; 49: 79-84.
21. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315-317. (Pubitemid 29204987)
22. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; CD006162.
23. Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N et al. Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese. Eur J Clin Invest 2010; 40: 121-126.
24. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567-1569. (Pubitemid 41279033)
25. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810-4819. (Pubitemid 350223464)
26. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010; 95: 911-919.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
28. Systéme International (SI) units for plasma, serum, or blood concentrations. Diabetes 1993; 42: 370-371.
29. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008; 1781: 200-212.
30. Matias I, Gonthier MP, Orlando P, Martiadis V, De PL, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180. (Pubitemid 44271774)
31. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008; 16: 553-565. (Pubitemid 351328005)
32. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; 158: 451-461.
33. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le FG, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914. (Pubitemid 36368998)
34. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.
35. Engeli S, Heusser K, Janke J, Gorzelniak K, Batkai S, Pacher P et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. Obesity (Silver Spring) 2008; 16: 1135-1137. (Pubitemid 351620487)
36. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009; 52: 213-217.
37. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008; 29: 229-233.
38. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity Diabetes 2005; 54: 2838-2843.